Company Overview and News

 
TransMontaigne Partners' (TLP) CEO Fred Boutin on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Hello and welcome to the TransMontaigne Partners First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation.

 
TLP / TransMontaigne Partners LP 8-K (Current Report)

2018-05-09 sec.gov
tlp_Current folio_8K

 
TLP / TransMontaigne Partners LP 10-Q (Quarterly Report)

2018-05-09 sec.gov
tlp_Current folio_10Q Table of Contents &nbs

 
30 Dividend Contenders Show 4.68-12.91% Yields Backed By 10-24 Years Of Increases

2018-05-09 seekingalpha
Broker target-estimated May Dividend Contender top-ten net-gains ranged 20%-43.7%, from BIP, QCOM, TCP, EPD, ENB, ETE, SEP, PM, TLP, and were topped by ETP as selected 4/30/18 and measured 5/7/18.

 
30 Dividend Contenders Show 4.68%-12.91% Yields Backed By 10-24 Years Of Increases

2018-05-09 seekingalpha
Broker target-estimated May Dividend Contender top-ten net-gains ranged 20%-43.7%, from BIP, QCOM, TCP, EPD, ENB, ETE, SEP, PM, TLP, and were topped by ETP as selected 4/30/18 and measured 5/7/18.

 
John And Jane - April Dividend Income Tracker - Taxable Account

2018-05-08 seekingalpha
This is the 6th month I have officially tracked dividend income, and it was slightly below expectations with a total of $619.98 of dividends received.

 
102 Dividend Achievers Yield 2.52%-11.65% For April/May

2018-05-01 seekingalpha
Dividend Achiever stocks are distinguished by 10 or more straight years of higher dividends. Some 265 Achiever equities are balanced by sector and capitalization. PFM is their tracking ETF.

 
Top MLP Losses in the Week Ending April 27

2018-05-01 marketrealist
SunCoke Energy Partners (SXCP), an MLP involved in coke manufacturing and logistics, was the top MLP loss in the week ending April 27. The partnership had weak earnings in 1Q18. The partnership posted an adjusted EBITDA of $49.5 million during 1Q18—compared to $51.7 million in 1Q17 The YoY decline was mainly driven by planned outage and maintenance costs in the partnership’s Domestic Coke segment. However, the partnership reaffirmed its 2018 adjusted EBITDA guidance of $215 million–$225 million.

 
 
John And Jane - March Dividend Income Tracker - Taxable Account

2018-04-03 seekingalpha
This is the 5th month I have officially tracked dividend income and it was slightly above expectations with a total of $929.59 of dividends received.

 
Bright Horizons Family Solutions downgraded to sector perform from outperform at RBC Capital

2018-04-03 marketwatch
For-profit education companies are poised to surge given the friendly approach of the Trump administration toward these companies. Adding a few stocks looks like a smart move.

 
50 Energy Sector Top-Yield Dividend Prospects For April

2018-04-02 seekingalpha
Midstream firms, Dominion, Sanchez, & Energy Transfer topped February's broker-vetted Energy Sector gains list, while Awilco Drilling, was tops by yield, as calculated 3/28/18.

 
 
TransMontaigne Partners' (TLP) CEO Fred Boutin on Q4 2017 Results - Earnings Call Transcript

2018-03-15 seekingalpha
Greetings and welcome to the TransMontaigne Partners Fourth Quarter and Full Year 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] And as a reminder, this conference is being recorded.

 
TLP / TransMontaigne Partners LP 8-K (Current Report)

2018-03-15 sec.gov
tlp_Current folio_8K

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 89376V100